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Background: Precocious development of Alzheimer-type neuropathological changes in epilepsy patients, especially
in APOE ε4,4 carriers is well known, but not the ways in which other APOE allelic combinations influence this
outcome. Frozen and paraffin-embedded tissue samples resected from superior temporal lobes of 92 patients
undergoing temporal lobectomies as a treatment for medication-resistant temporal lobe epilepsy were used in this
study. To determine if epilepsy-related changes reflect those in another neurological condition, analogous tissue
samples harvested from 10 autopsy-verified Alzheimer brains, and from 10 neurologically and neuropathologically
normal control patients were analyzed using immunofluorescence histochemistry, western immunoblot, and real-
time PCR to determine genotype effects on neuronal number and size, neuronal and glial expressions of amyloid β
(Aβ) precursor protein (βAPP), Aβ, apolipoprotein E (ApoE), S100B, interleukin-1α and β, and α and β secretases; and
on markers of neuronal stress, including DNA/RNA damage and caspase 3 expression.
Results: Allelic combinations of APOE influenced each epilepsy-related neuronal and glial response measured as
well as neuropathological change. APOE ε3,3 conferred greatest neuronal resilience denoted as greatest production
of the acute phase proteins and low neuronal stress as assessed by DNA/RNA damage and caspase-3 expression.
Among patients having an APOE ε2 allele, none had Aβ plaques; their neuronal sizes, like those with APOE ε3,3
genotype were larger than those with other genotypes. APOE ε4,4 conferred the weakest neuronal resilience in
epilepsy as well as in Alzheimer patients, but there were no APOE genotype-dependent differences in these
parameters in neurologically normal patients.
Conclusions: Our findings provide evidence that the strength of the neuronal stress response is more related to
patient APOE genotype than to either the etiology of the stress or to the age of the patient, suggesting that APOE
genotyping may be a useful tool in treatment decisions.
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Epilepsy is the third most common cause of neurological
disability worldwide [1] and is associated with pre-
cocious development of the neuropathological changes
of Alzheimer’s disease (AD) [2-4]. Traumatic brain in-
jury (TBI), which is a major risk factor for the develop-
ment of epilepsy [5], is also associated with increased
risk for later development of AD, and, in both cases, the
risk of development of AD is greater with inheritance of* Correspondence: griffinsuet@uams.edu
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reproduction in any medium, provided the orapolipoprotein E ε4 alleles (APOE ε4) [3,6]. Exploring
possible links between epilepsy-related alterations in neur-
onal and glial cell responses relative to APOE genotype is
potentially important in understanding chronic neurode-
generative sequelae in epilepsy as well as in other forms of
brain injury such as TBI [5,7-10].
In both purified rodent neuronal cell cultures and cul-
tures of the human neuroblastoma cell line NT2, excess
glutamate induces marked increases in the expression of
the neuronal acute phase response protein βAPP, and in
the release of its secreted fragment sAPPα [11], which is a
powerful inducer of glial activation and increased produc-
tion and release of the proinflammatory cytokine IL-1β
[12]. This sAPP-induced glial activation and cytokine
expression and release is differentially modulated in theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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greater protection than ApoE4. In epilepsy, there is
overexpression of βAPP and IL-1, as well as the astrocyte-
derived, neuritogenic cytokine S100B [13,14]. Further-
more, a comparison between surgical waste tissues from
patients undergoing anterior temporal lobectomy surgery
for drug-resistant intractable epilepsy showed that APOE
ε3,3 and APOE ε4,4 genotypes dramatically alter the ex-
pression of βAPP and of IL-1 such that the APOE ε3 allele
is more effective with regard to the maintenance of appro-
priate neuronal acute phase responses that favor neuronal
viability than is APOE ε4 [2]. Importantly, several studies
have provided evidence that inheritance of an APOE ε4
allele is associated with increased risk for Alzheimer
neuropathological changes in epilepsy patients [3]. This is
particularly relevant to the possibility that the decrease in
the ability of ApoE4 compared with ApoE3 to elevate syn-
thesis of the neuronal acute phase protein βAPP [15] is
responsible for less sAPPα release, resulting in diminished
neuronal repair and survival [16].
Epilepsy, in particular, exemplifies the intimate rela-
tionship between neuronal stress and triggering of glial
activation, as such interactions are self-amplifying in epi-
lepsy. For example, glutamate-induced hyperexcitation
in purified primary rat neurons results in increases in
βAPP, sAPP, and IL-1β, as well as ApoE, and both IL-1β
and ApoE induce βAPP expression and sAPP release.
Moreover, IL-1β treatment of neurons results in glutam-
ate release [17], promoting a proposed self-perpetuating
series of events: glutamate→ApoE→ βAPP→ sAPP→
IL-1β→ glutamate. Initially, cycle-engendered early
acute phase responses may be beneficial, affording neur-
onal protection and debris clearance. However, because
of the self-perpetuating nature of this cycle and the result-
ant glutamate release from both glia [18] and neurons [17]
chronic neuronal stress ensues, enhancing the probability
of neurodegeneration. Furthermore, the potential of such
a cycle to be self-regenerative may explain, at least in part,
why even those epilepsy patients with the advantage of an
APOE ε3,3 genotype may develop Alzheimer-type neuro-
pathological changes.
Evidence of a role for APOE genotype in determining
neurodegenerative consequences of epilepsy underscores
the need for in-depth analyses of neuronal-glial interac-
tions that may be governed by inheritance of specific
APOE allelic combinations. Such analyses provide basic
cellular and molecular information regarding pathways
involved in neuronal-glial interactions as well as infor-
mation that may be helpful in clinical decision making.
Results
Comparison between our patient groups – Group 1: pa-
tients having one or two alleles of ε2 and no ε4 [APOE
ε2,2 (n = 1) and APOE ε2,3 (n = 12)] age range = 14 y-73 y,median age = 40 y, average age = 35 y; Group 2: [APOE
ε3,3 patients (n = 53)], age range = 0.25 y-71 y, median
age = 32 y, average age = 30.4 y; Group 3: patients having
one ε4 allele [APOE ε2,4 (n = 2) APOE ε3,4 (n = 17)], age
range = 10 y-48 y, median age = 30.5 y, average = 29.2 y;
Group 4: [APOE ε4,4 patients (n = 7)], age range = 10 y-50 y,
median age = 34 y, average age = 32 y. Such grouping
allowed for investigation of the degree of influence of
each of the 6 combinations of the three APOE alleles
and provided the following results.
APOE genotype modulation of glial responses in epilepsy
Glial numbers in a given cross-sectional cortical area
Patients in Group 1 (patients having one or two alleles of
ε2 but no ε4) had the lowest number of microglia per
neuron: 82% of the neurons had less than two adjacent
microglia. Relative to other groups, Group 2 (patients with
two APOE ε3 alleles ε3,3) had more IL-1α-immunoreactive
microglia adjacent to each neuron: 70% of the neurons had
at least two adjacent microglia, with some having as many
as 9. In Group 3 (patients having one APOE ε4 allele, ε2,4
and ε3,4), more than 80% of neurons had two or less
IL-1α immunoreactive microglia per neuron. In Group 4
(patients having two APOE ε4 alleles, ε4,4), 70% of neu-
rons had one or fewer adjacent microglia (Figure 1).
In a given unit area of cortical layers III and IV of super-
ior temporal gyrus in patients in Group 2 (patients having
two APOE ε3 alleles), the total number of microglia
counted was greater than that in other groups (Group 2 =
1137 ± 267 vs Group 1 = 460 ± 112; Group 3 = 534 ± 81;
Group 4 = 770 ± 187 microglia/mm2; p < 0.001). Although
the number of microglia/mm2 was influenced by APOE
genotype, the relative levels of glial cytokine mRNAs IL-1α
and IL-1β were not related to genotype (data not shown).
Astrocyte numbers per unit area were highest in pa-
tients with APOE ε3,3 (Group 2) compared to those in
patients with other APOE allelic combinations, groups 1,
3, and 4 respectively (175 ± 19 vs 94 ± 38; 96 ± 12; 133 ±
12 astrocyte/mm2; p < 0.001). However, synthesis of the
astrocyte-derived cytokine S100B was higher in patients
with APOE ε4,4 compared to that in patients carrying other
allelic combinations (Figure 2A). Conversely, S100B protein
expression was higher in APOE ε3,3 (Group 2) patients
(99.7 ± 5.17) than in groups 1, 3, or 4, respectively (95.7 ±
3.55, 92.7 ± 6.21, 92.9 ± 2.87; p < 0.001) (Figure 2B and C).
APOE genotype modulation of neuronal responses in
epilepsy compared to that in Alzheimer patients
Neuronal numbers in a given cortical area and neuronal
cross-sectional area in epilepsy
As previously reported [2], we observed no differences in
neuronal numbers between epilepsy patients with either
an APOE ε3,3 or APOE ε4,4 genotype. However, the
cross-sectional area of neurons from patients in Group 1
Figure 1 The relationship between neuronal expression of ApoE and glial expression of IL-1α, relative to APOE genotype. IL-1α (green)-
immunoreactive microglia clustered around individual ApoE-immunoreactive neurons (red) in patients with APOE ε2,3 (A), APOE ε4,4 (B), APOE ε3,4
(C), and APOE ε3,3 (D). A maximum of 9 microglia per neuron were counted in APOE ε3,3 patients (arrow in D); this was higher than the numbers
associated with other APOE genotypes as shown in the percentage of neurons with adjacent IL-1α immunoreactive neurons (none to nine) relative to
APOE genotype (E).
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alleles, but no APOE ε4 allele, or those having APOE ε3,
3 genotype, respectively) was greater (439 ± 32 μm2 vs
389 ± 29 μm2). APOE ε4,4 neurons (Group 4) had the
smallest neuronal area (213 ± 17 μm2) among the Groups,
p < 0.001 (Figure 3).Figure 2 APOE genotype influences expression of the astrocyte-deriv
S100B mRNA levels in patients with APOE ε4,4 (Group 4) is higher than tha
p = 0.001; and Group 4 vs 3, p = 0.004 (A). S100B protein levels for all the p
APOE ε3,3 patients (Group 2, n = 53) had higher levels of S100B than did o
arbitrary units; p = 0.001) for groups 1 (n = 13), 3 (n = 19), and 4 (n = 7), res
blots of different epilepsy samples (n = 92) with standard (Std) purified S1
represents the S100B monomer (~11kD) (C).Neuronal numbers in a given cortical area and neuronal
cross-sectional area in Alzheimer patients vs control
patients
In tissue from patients with Alzheimer’s disease, the sizes
of APOE ε3,3 neurons were larger than those of APOE
ε4,4 neurons (286 ± 23 μm2 vs 227 ± 25 μm2, p < 0.01)ed neuritogenic cytokine S100B. Wilcoxon distribution scores for
t in other genotypes. p values: Group 4 vs 1, p = 0.004: Group 4 vs 2,
atient samples (n = 92), quantified by western blot, showed that
ther APOE genotypes (99.7 ± 5.17 vs 95.7 ± 3.55, 92.7 ± 6.21, 92.9 ± 2.87
pectively (B). Illustration of S100B protein levels; one of eight western
00B positive control (middle sample S100B Std) the S100B mono band
Figure 3 Epilepsy-induced neuronal stress affects neuronal size in an APOE genotype-dependent fashion. Neurons in tissue from
epilepsy patients were immunoreacted with a pan neuronal marker (green). The apparent large size of neurons in patients with APOE ε2,3
(A) and those in patients with APOE ε3,3 (B) relative to those in patients with APOE ε2,4 (C), APOE ε3,4 (D), and APOE ε4,4 genotype (E) was
confirmed by measuring cross-sectional areas of neurons (μm2) in Groups 1,2,3,4, respectively (432 ± 40; 389 ± 29; 294 ± 20; vs 213 ± 17;
p < 0.001) (F).
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logous tissue from neurologically normal controls did
not differ with APOE genotype (APOE ε3,3 neurons,
293 ± 32 μm2 and APOE ε4,4 neurons, 282 ± 21 μm2)
(Figure 4D-F). The cross-sectional area of APOE ε4,4
neurons was less than that of APOE ε3,3 neurons in
both epilepsy and Alzheimer patients, perhaps sug-
gesting that APOE ε4,4 neurons are not able to follow
the same response to neuronal stress as do neurons of
other genotypes. No APOE genotype-related changes in
neuronal cell numbers were detected in our epilepsy
patient Groups 1,2,3, and 4 (302 ± 39, 277 ± 25, 280 ±
32, 272 ± 21 per mm2, respectively).
Neuronal impairment in epilepsy
APOE genotype-related RNA/DNA oxidative damage,
measured as 8-OH guanosine intensity was examined in a
small sample of our patients that was somewhat reflective
of the rarity of APOE genotypes among our patients and
among the general population [APOE ε2,2 (n = 1); APOE
ε3,3 (n = 10); and APOE ε4,4 (n = 4) genotypes]. This ana-
lysis showed that there was less oxidative damage to DNA
in tissue from epilepsy patients with genotypes other than
APOE ε4,4 (55 ± 6 and 55 ± 6 vs 80 ± 3 arbitrary units, re-
spectively, p < 0.01) (Figure 5), even though this indication
of cellular stress is not necessarily followed by DNA frag-
mentation [19]. Assessment of epilepsy-related neuronal
cell death pathways (measured by western blot analysis of
caspase 3 levels in all samples) showed that caspase 3 levels
were lower in APOE ε3,3 patients (Group 2) than in Groups
1, 3, or 4, respectively (8.4 ± 4.1 vs 13.2 ± 4.0, 11.7 ± 2.4,
14.4 ± 4.0, p < 0.05) (Figure 6).Acute phase responses in epilepsy relative to APOE
genotype
To assess the neuronal response to the hyperexcitation
stress in epilepsy, we measured the relative tissue levels
of the messenger RNAs for both βAPP and ApoE in
tissue samples from patients (n = 92) with each of the
different APOE allelic combinations, using real time
PCR analysis. βAPP mRNA expression did not show sig-
nificant differences with regard to APOE genotype (data
not shown). However, ApoE mRNA levels were higher
in Group 4 (the APOE ε4,4 group) than in other groups
(Figure 7A). Despite the lack of increased expression of
βAPP mRNA among our patients, there was a dramatic
increase in the levels of βAPP protein in those with
APOE ε3,3 (Group 2) compared to those levels in APOE
ε4,4 (Group 4), suggesting that the elevation of βAPP in
this group was due more to translation than transcrip-
tion. Conversely, ApoE protein levels, measured by
western blot analysis showed that APOE ε4,4 patients
(Group 4) had lower levels than did other APOE geno-
types (18.2 ± 8.4 vs 61.8 ± 15.3, 55.4 ± 23.3, 26.9 ± 7.1;
Group 4 vs 1, 2, and 3, respectively, p < 0.01) (Figure 7B,C),
suggesting that even the increase in ApoE mRNA in tis-
sues samples from Group 4 patients was not sufficient
to raise ApoE protein levels to those noted in other
groups. Moreover, Group 4 (APOE ε4,4) patients had
lower tissue levels of actin than did patients in Groups
1, 2, and 3, respectively (57.0 ± 13.0 vs 83.8 ± 13.0, 114.3 ±
39.5, 106.1 ± 19.0, p < 0.01). This may explain, at least in
part, the differences noted in neuronal size. For ex-
ample, without regard to cell type, size may influence
actin levels. Alternatively, actin levels may influence cell
Figure 4 Cross sectional neuronal area in Alzheimer patients and in neurologically normal controls, relative to APOE genotype. Superior
temporal gyrus tissue sections from Alzheimer patients (A-C) and neurologically normal patients (D-F) immunoreacted with Pan neuronal marker
(green) in Alzheimer patients having APOE ε3,3 (A) appeared to be larger than those from Alzheimer patients with APOE ε4,4 (B). Cross-sectional
area measurements of neurons (μm2) confirm this difference (286 ± 23, vs 227 ± 25; p = 0.009) (C). Cross-sectional area of neurons in control
patients with APOE ε3,3 (D) was not different from that in control patients with APOE ε4,4 (E) (250 ± 16, vs 244 ± 28; p = 0.67) (F).
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studies [20].
The influence of APOE genotypes on epilepsy-induced
neuropathological changes
None of the 15 patients having at least one APOE ε2 allele
had Aβ plaques. This is in contrast to the fact that Aβ
plaques were present in carriers of all other genotypes [13Figure 5 Neuronal stress as estimated by heat shock-related damage
neurons expressing RNA/DNA oxidative damage was similar in the differen
neuron, as assessed by Stress Marq (8-OH guanosine) fluorescence intensity
genotypes (80 ± 3 vs 55 ± 6 and 55 ± 6 arbitrary units, p = 0.001) (D).of the 53 patients with APOE ε3,3, 24.5%; 3 of 17 patients
with APOE ε3,4, 17.6%; and in 1 of the 6 patients with
APOE ε4,4, 16.7% (one of the seven APOE ε4,4 patients
was not examined immunohistochemically because of a
limited amount of tissue)] (Figure 8A-C). These findings
raise the possibility of a protective role of APOE ε2 alleles
against plaque formation in epilepsy. The elevated plaque
density in those with APOE ε3,3 and APOE ε3,4 comparedassociated with expression of 8-OH guanosine. Numbers of
t APOE genotype groups (A-C). However, the extent of damage per
, was greater in patients with APOE ε4,4 than APOE ε2,2 or ε3,3
Figure 6 APOE genotype influences cell cycle-related DNA damage. Illustration of a western blot representative of 8 gels from patients
(n = 92) with different APOE genotypes, showing actin bands (green) and pro-caspase 3 bands (red) (A). Wilcoxon distribution scores for pro-
caspase 3 fluorescence intensity for all the 92 patients: APOE ε3,3 (Group 2) had lower levels of pro-caspase than other genotypes (B) with p
values for comparisons with Groups 1,3,4 equal to < 0.002, < 0.001, and < 0.02, respectively.
Figure 7 ApoE transcription and translation relative to APOE genotype. Wilcoxon distribution scores for ApoE mRNA levels were higher in
patients carrying at least one APOE ε4 allele (Group 3 and Group 4) than in those carrying other APOE genotypes (Groups 1 and 2); the difference
was significant only between Group 2 and Group 3 (p < 0.01) (A). ApoE protein levels, illustrated in one of eight western blots of different
epilepsy samples (n = 92) with actin (red) in the upper row and ApoE (green) in the lower row with the middle sample being recombinant ApoE
protein used as a positive control (Std) (B). ApoE protein levels for all the patient samples (n = 92), quantified by western blot analysis, showed
that APOE ε4,4 patients (Group 4) had lower levels of ApoE than did other APOE genotypes (18.2 ± 8.4 vs 61.8 ± 15.3, 55.4 ± 23.3, 26.9 ± 7.1
arbitrary units) for groups 1, 2, and 3, respectively, p < 0.01 (C).
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Figure 8 Neuropathological changes in epilepsy relative to APOE genotype. Multiple IL-1α (green)/ApoE (red)-immunoreactive plaques
were present in 13 of the 53 APOE ε3,3 patients (A) – the youngest of which was 17 yrs old – and in 3 of the 17 APOE ε3,4 patients (not shown
here). One of the six APOE ε4,4 patients had Aβ plaques, a 10 year old male (B). The incidence of plaques in patients having each of the APOE
allelic subtypes (C). Wilcoxon distribution scores for α-secretase mRNA measured relative to 18s mRNA showed that APOE ε4,4 patients (Group 4)
had higher levels than did other APOE genotypes, with p values of 0.02, 0.01, and 0.01 for comparisons between group 4 and groups 1, 2, and 3,
respectively (D).
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patients of elevated ApoE and S100B; both induce ele-
vation of βAPP expression, which is then available for Aβ
cleavage and deposition. Although APOE genotype did
not influence expression of the mRNAs for the β-
secretases (BACE1 and 2), α-secretase mRNA expression
was elevated in those with APOE ε4,4 genotype (Group 4)
compared to other genotypes (Figure 8D). The APOE
ε4,4-related increase in α-secretase mRNA expression
might be viewed as an attempt at compensation for other
deficiencies as α-secretase obviates the production of Aβ
and at the same time increases secretion of sAPPα, which
may provide a neuron-sparing action [16]. It is interesting
to note that in epilepsy with the early appearance of Aβ
plaques and glial activation, there is little or no evidence
of neurofibrillary tangle formation [21].
Discussion
Our results show that, compared to other APOE allelic
combinations, neuronal resilience and glial activation
were greatest in epilepsy patients with APOE ε3,3 geno-
type. Neuronal resilience correlated with the highest
expression of acute phase response proteins βAPP and
ApoE, greatest neuronal size, and least indications of
DNA fragmentation, oxidation, and potential cell cycling.
Similarly, compared to patients with other allelic combi-
nations, patients with APOE ε3,3 genotype had more IL-
1α-immunoreactive microglia in a given cross-sectional
cortical area, more microglia adjacent to neurons, andmore astrocytes per given cross-sectional area. In addition,
the tissue levels of the astrocyte-derived, neuron-sparing
neuritogenic cytokine S100B were highest in patients with
APOE ε3,3 genotype. These findings are consistent with
the idea that APOE genotype influences neural responses
to the neuronal stress engendered by the hyperexcitation
of epilepsy. Several neural stresses elicit elevation of neur-
onal acute phase proteins βAPP and ApoE, which, in turn,
promote microglial and astrocytic activation with in-
creased expression of glial cytokines such as IL-1β and
S100B. These cytokines are known to regulate the expres-
sion of each other and both are known to induce the
expression of βAPP and ApoE for promotion of neuronal
survival and maintenance [15,17,22-24]. Together, our
findings are consistent with the idea that hyperexcitation
first elicits compensatory responses that include over-
expression of βAPP, release of sAPP, and glial activation
with induction of IL-1 and S100B. The fact that carriers of
one or two APOE ε3 allele(s) were shown here to be more
adept than carriers of other APOE genotypes at eliciting
specific neuronal and glial responses that have been asso-
ciated with neuronal repair and survival [16,25] suggests
that neuronal resilience is, at least in part, dependent on
which specific ApoE variant is present.
Our findings that inheritance of two APOE ε4 alleles is
associated with smaller neurons in both epilepsy and
Alzheimer’s disease, but not in neurologically normal
controls, together with the dramatic elevation of markers
of stress in APOE ε4,4 carriers, suggests that such
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gardless of the initiating injury. Elevated expression of
ApoE mRNA, in conjunction with a lower expression of
ApoE protein in those with APOE ε4,4 genotype may
represent a failed attempt to increase ApoE expression
as a way of increasing βAPP expression, which in itself
may be futile as ApoE4 has been shown to be an inef-
fective stimulant of βAPP expression [15].
The Aβ plaques and hippocampal atrophy in temporal
lobectomy tissues from epilepsy patients have been ob-
served in other studies [4,26]. Our finding that the inci-
dence of Aβ plaques is dependent on specific APOE
allelic subtypes, namely, that having even one APOE ε2
allele is associated with an absence of Aβ plaques even
in our oldest patient (71y), may in some way be related
to a reported decreased risk for AD [27] and a protective
effect of inheritance of APOE ε2 against Alzheimer-like
neuropathological changes [28]. The Aβ plaques, which
were noted in our 10-year old APOE ε4,4 patient,
appeared to be mature dense core neuritic plaques, while
those in carriers of other allelic combinations appeared as
diffuse neuritic plaques. These findings support previous
studies showing a relationship between the presence of an
APOE ε4 allele and precocious development of AD in
epilepsy patients [3,29], and suggests the need for further
investigation into the role of APOE ε4 alleles in Aβ plaque
maturation. These findings may have relevance to the fact
that plaque maturity is associated with both formation of
Aβ dense cores as well as increases in ApoE immunoreac-
tivity as Aβ plaques mature [30].
The fact that most of the Aβ plaques present in our
patients were found in APOE ε3,3 carriers may, in
principle, be mostly related to increases in βAPP expres-
sion, especially in view of concomitant increases in pro-
teins, cytokines, and neurotransmitters that are known
to induce increases in neuronal βAPP, viz., ApoE [15],
IL-1 [17], S100B [23], and glutamate [17], perhaps identi-
fying mechanisms by which the advantage of having
APOE ε3 alleles may be accompanied by the disadvantage
of fostering Aβ deposition. Interestingly, with regard to
APOE genotype and Alzheimer neuropathological change,
carrying even one APOE ε2 allele appears to have a
protective effect against the formation of Aβ plaques,
regardless of age and sex. These interpretations of our
results are predicated on the idea that Aβ plaques are the
consequence of hyperexcitation-induced, neuronal stress-
related cycles that are important in the neuropathological
progression observed in epilepsy and which occur as a
consequence of disease severity and duration, perhaps
regardless of genotype, age, and sex. Our observation re-
garding greater plaque maturity among those with APOE
ε4,4 relative to other APOE genotypes is consistent with
observations in Alzheimer patients [31,32] and in mice
[33], which show that ApoE binding to Aβ disrupts Aβclearance across the blood-brain barrier in an isoform-
specific manner, with ApoE4 having a greater disruptive
effect than ApoE3 or ApoE2 [33].
The lower tissue levels of actin in patient carriers of
APOE ε4,4 compared to those with other APOE allelic
combinations may explain, at least in part, the APOE ε4,4-
related smaller neuronal cell size [20]. Variation in actin
expression according to APOE genotype, as we show here,
suggests that actin should not be used as a tool for nor-
malizing the relative expression of proteins in situations in
which actin varies with specific parameters.
Conclusions
Our finding that even one APOE ε2 allele is protective
against Aβ plaque deposition is consistent with previous
reports associating this genotype with protection against
Alzheimer’s disease [34]. The robust neuronal-glial re-
sponse to the neuronal stress of epilepsy in APOE ε3,3
carriers suggests that overall they have an advantage over
other genotypes as indicated by an ability to increase
neuronal acute phase protein expression, a greater neur-
onal size, and increased resilience, as indicated by lower
levels of markers for RNA and DNA damage, and lower
susceptibility to inappropriate cell cycling and death path-
ways. However, the fact that the percentage of patients
with Aβ plaques was highest in APOE ε3,3 carriers sug-
gests that these beneficial effects occur at the expense of
an increase in the possibility of cleavage of excess βAPP
and formation of Aβ, as well as increasing deposition of
ApoE in such plaques and in this way perhaps favoring
plaque formation. APOE ε4,4 carriers in our study were
disadvantaged compared to other genotypes, having the
smallest neurons among the genotypes, lowest acute phase
responses, and highest markers of stress. Taken together,
our findings suggest that APOE genotype may be import-
ant in decisions regarding timing of surgical intervention
for intractable epilepsy, as well as in decisions regarding




Resected temporal lobe tissues were obtained from 92 epi-
lepsy patients (58 males and 34 females; 1 APOE ε2,2, 12
APOE ε2,3, 53 APOE ε3,3, 2 APOE ε2,4, 17 APOE ε3,4
and 7 APOE ε4,4) with an age at surgery ranging from
0.25 to 73 years (median age = 32 y, average age = 31.7 y).
All patients underwent anterior temporal lobectomy for
treatment of medication-resistant intractable epilepsy. For
more information on patients regarding neuropathological
evaluation please see [35]. Surgical waste obtained from
the anterior portion of the superior temporal gyrus, an
area some distance from sclerotic areas and epileptogenic
foci, was dissected at 4 mm intervals, and alternate
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analyses and by formalin fixation for histological evalu-
ation. For uniformity, immunohistochemical examination
was restricted to cortical layers III and IV of superior tem-
poral gyrus.
Autopsy tissue samples
Temporal lobe tissues analogous to that collected from
epilepsy surgical waste was collected from autopsied
brain tissue of neuropathologically diagnosed Alzheimer
patients [n = 6 males and n = 4 females; 5 APOE ε3,3
(M-60 y; M-73 y; F-76 y; F-80 y; F-88 y) and 5 APOE
ε4,4 (F-72 y; M-74 y; M-74 y; M-82 y; M-86 y]. Analo-
gous tissue samples were also obtained from neurologic-
ally and neuropathologically normal individuals [n = 8
males and n = 2 females; 6 APOE ε3,3 (M-69 y; M-78 y;
M-78 y; M-81 y; M-83 y; F-87 y) and 4 APOE ε4,4
(M-70 y; M-78 y; F-79 y; M-85 y)]. As with the pro-
cessing of the tissue samples from our epilepsy patients,
autopsy tissue samples collected less than eight-hours
postmortem from Alzheimer and control patients were
identical, i.e., analogous samples to be used for molecu-
lar analyses were snap frozen in liquid nitrogen and for
immunohistochemical analyses sections of formalin
fixed brains were used.
Surgical waste and autopsy tissue are both exempt from
IRB review under 46.101 5(b), and this study was ap-
proved as an exempt study by the University of Arkansas
Institutional Review Board.
For further analysis of data obtained from epilepsy pa-
tients, we categorized genotypes into four groups. Group 1:Table 1 Human gene sequences for ApoE, βAPP, α-secretase,
annealing temperatures and number of amplification cycles





α-secretase (ADAM 10) F: AGTGTACGTGTGCCAGTTC
R: TTGCAGGGTGATGGTTCG
BACE 1 F: CAGTCAAATCCATCAAGGCAG
R: GTTGGTAACCTCACCCATTAGG
BACE 2 F: AGAGTATAACGCAGACAAGGC
R: CCAGTCCAGAAACCATCAGAG
IL-1 α F: GGAGAGCATGGTGGTAGTAGCAA
R: TGGCTTAAACTCAACCGTCTCTT
IL-1 β F: GCACGATGCACCTGTACGAT
R: CACCAAGCTTTTTTGCTGTGAGT
S100B F: CCCCAGGGACTCTTGTTAACAG
R: CACGGTGCACGCTTTATCACpatients having one or two alleles of ε2 and no ε4 [APOE
ε2,2 (n = 1) and APOE ε2,3 (n = 12)]; Group 2: [APOE ε3,3
patients (n = 53)]; Group 3: patients having one ε4 allele
[APOE ε2,4 (n = 2) APOE ε3,4 (n = 17)]; Group 4: [APOE
ε4,4 patients (n = 7)]. This grouping allowed for investiga-
tion of the degree of influence of each of the three APOE
alleles on observed results.
Immunofluorescence immunohistochemistry
Reagents: Antibodies: rabbit anti-human IL-1α (Peprotech
4:1000): goat anti-human ApoE (Invitrogen 1:50): mouse
anti-human Aβ/βAPP (Covance 1:1000); rabbit anti-
human Pan Neuronal Marker (PNM – Millipore ABN
1:500); mouse anti-human DNA/RNA oxidative damage
antibody (8-OH-gaunosine – Stress Marq Biosciences
5 μg/ml); rabbit anti-phosphorylated tau (AT8 – Abcam
1:3000); rabbit anti-actin (Santa Cruz 1:1000) were diluted
in antibody diluent (DAKO). Secondary antibodies were
Alexa Fluor® 488: donkey anti-rabbit or goat anti-rabbit;
Alexa Fluor® 594: donkey anti-goat or goat anti-mouse.
Mounting media containing Prolong Gold anti-fade re-
agent with DAPI (Invitrogen) was used to stain nuclei.
Procedures
Paraffin-embedded tissue was sectioned at 7 μm and
processed as previously described [2]. Sections destined
for IL-1α, PNM, Stress Marq, and Aβ immunoreaction
were pretreated by placing them in boiling sodium cit-
rate buffer (0.01 M, pH 6.0) for 20 minutes; sections for
ApoE immunoreaction were placed in trypsin solution for
10 min at 37°C, and all were blocked using protein blockBACE 1, BACE 2, IL-1α, IL-1β, and S100B, with PCR
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room temperature. Appropriate Alexa Fluor-tagged sec-
ondary antibodies were diluted in antibody diluent 1:200,
and sections were incubated for 60 minutes, washed three
times for 5 minutes each in distilled water, and cover-
slipped with prolong Gold with DAPI.
Image analysis
As previously described [2,15], a quantitative approach
was used to assess numbers of glia and neurons. Three
images per slide (40× magnification) were captured at
identical exposure settings using a Nikon Eclipse E600
microscope equipped with a Coolsnap monochrome cam-
era. Each of the three images, spanning 37,638.6 μm2, was
acquired, analyzed, and thresholded using NIS-Elements
BR3 software (Nikon.com). Results regarding neuronal
and glial numbers are presented as numbers/mm2. Data
were analyzed by ANOVA to assess differences among
groups. Significance was provided by p ≤ 0.05.
Real time (RT) polymerase chain reaction (PCR)
amplification
Total RNA was extracted from brain tissue using
TriReagent™ RNA (Molecular Research Center, Cincinnati,
OH), according to the manufacturer's instructions. Real-
time RT-PCR was performed as previously described [15].
Briefly, for comparisons of mRNA levels among different
RNA samples, RT reactions were performed simultan-
eously using reagents from Life Technologies (Grand
Island, NY). RT-PCR was performed using reagents from
SyberGreen Master Mix from Life Technologies (Grand
Island, NY). The sequences of primers for ApoE, βAPP, α-
secretase (ADAM 10), BACE 1, BACE 2, IL-1α, IL-1β, and
S100B are given in Table 1. Equal amounts of RT-PCR
from each sample were pooled to use for standard curve
reaction with each primer set to verify linearity and a suit-
able slope. All given mRNA tissue levels are relative to 18s.
Western immunoblot assay
Proteins were extracted from brain tissue in a lysis buf-
fer comprised of 20 mM Tris-HCl (pH 7.5), 150 mM
NaCl, 1% Nonidet P40, 1 mM EGTA, 1 mM EDTA, and
1% sodium deoxycholate; lysate protein was quantified
using a Micro BCA assay reagent kit (Pierce, Rockford
IL) as described previously [2]. Aliquots (30 μg each
for ApoE and 50 μg for caspase 3) were loaded onto a 4-
12% CriterionXT precast Gel Bis-Tris from Bio-Rad
(Hercules, CA), subjected to electrophoresis at 80V for
3 h, and transferred to PVDF 0.45 μm Immobilon-FL
(Millipore). Blots were blocked in I-Block Buffer (Ap-
plied Biosystem Inc., Bedford, MA) for 60 minutes, then
incubated overnight at 4°C with either mouse monoclo-
nal anti-ApoE (1:500) (Santa Cruz sc-58242) primary
antibody, rabbit anti-human Caspase3\Cleaved Caspase3 (1:500) (Cell Signaling # 9661-2), or rabbit anti-actin
(Santa Cruz 1:1000), and incubated for 1 h at room
temperature with alkaline phosphatase-conjugated sec-
ondary antibody (1:1000). For protein detection, we used
ProteinSimple Multifluor Western Blotting Kit (Santa
Clara, CA), and for image capture we used CellBioscience
FluorChem Q digital imager (Santa Clara, CA). Autora-
diographs were digitized and analyzed using NIH Image
software, version 1.60.
Statistical analysis
Data were analyzed using an unpaired t-test and
Wilcoxon distribution score, and results are expressed
as mean + SD. In the Wilcoxon distribution plot, the
length of the box represents the interquartile range (the
distance between the 25th and 75th percentiles), the
symbol in the box interior represents the group mean,
the horizontal line in the box interior represents the
group median, the vertical lines (the whiskers) issuing
from the box extend to the group minimum and max-
imum values. Values were considered significantly dif-
ferent when the p-value was ≤ 0.05.
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